FDA's Drug and Device Review Process: Hearing Before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, Second Session, February 6, 1992, Volume 4 |
Other editions - View all
Common terms and phrases
advisory committee meeting Agency agency's Alzheimer's disease analysis application Arthritis Advisory asked audit BARTON believe Bruce Burlington cells Center for Devices Center for Drugs Chairman clinical investigators clinical trial conduct CONG CONGRES CONGRESS THE LIBRARY consultant correct CTCL D-penicillamine DD SAN FRAN December decision DECOLA Dermatology DINGELL Director discussion disease DN BETHESDA Drug Administration drug development Drug Evaluation EDELSON effective Evaluation and Research FDA approval FDA review FDA's Food and Drug FRAN CA 415 Freundlich GRESS Harter issues January January 17 January 23 letter LIBRA LIBRARY OF CONGRESS months panel meeting participate patients PECK Phase III study Photopheresis treatments placebo problems Progressive Systemic Sclerosis questions RARY received record requested response RESS THE LIBRARY review process rheumatologist Rook ROWLAND scheduled scientific scleroderma sponsor staff statement study design subcommittee submitted Therakos therapy tion treated University of Pennsylvania Weisman WINTROUB